Literature DB >> 16103482

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

Caroline Robert, Sandrine Faivre, Eric Raymond, Jean-Pierre Armand, Bernard Escudier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16103482     DOI： 10.7326/0003-4819-143-4-200508160-00021

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  11 in total

1.  Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Authors:  Rena C Zuo; Andrea B Apolo; John J DiGiovanna; Howard L Parnes; Corrine M Keen; Swati Nanda; William L Dahut; Edward W Cowen
Journal:  JAMA Dermatol       Date:  2015-02       Impact factor: 10.282

Review 2.  Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

Authors:  Sylvie Négrier; Eric Raymond
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

3.  Acral lesions in tuberous sclerosis complex: insights into pathogenesis.

Authors:  Capt Shelley L Aldrich; Chien-Hui Hong; Leslie Groves; Cara Olsen; Joel Moss; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2010-05-11       Impact factor: 11.527

4.  Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.

Authors:  Catherine Delbaldo; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal:  Ther Adv Med Oncol       Date:  2012-01       Impact factor: 8.168

5.  Blackberry-induced hand-foot skin reaction to sunitinib.

Authors:  Susan L Boone; Gayle Jameson; Daniel Von Hoff; Mario E Lacouture
Journal:  Invest New Drugs       Date:  2008-11-08       Impact factor: 3.850

Review 6.  Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

Authors:  S E Rosenbaum; S Wu; M A Newman; D P West; T Kuzel; M E Lacouture
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

7.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

8.  Sorafenib-associated facial acneiform eruption.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-12-25

9.  Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab.

Authors:  Maudy Walraven; Marjolein Y V Homs; Astrid A M van der Veldt; Henk Dekker; Jose Koldenhof; Richard Honeywell; Arjan Barendrecht; Silvie A E Sebastian; Naomi Parr; Arnold C Koekman; Emile E Voest; Mark Roest; Suzanne J A Korporaal; Henk M W Verheul
Journal:  Angiogenesis       Date:  2018-03-12       Impact factor: 9.596

Review 10.  Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.

Authors:  Naomi B Haas; Robert G Uzzo
Journal:  Curr Treat Options Oncol       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.